Alizyme

21 Apr 2005

Nomura is leading a £30.5m capital increase for Alizyme, which develops treatments for obesity and gastrointestinal complaints.

Shareholders will be offered 30.5m shares in the company, equal to about 21% of its share capital, on a four-for-19 basis at a subscription price of 100p, a ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial